CAR-NK cell therapy

What CAR-NK products are

Chimeric antigen receptor (CAR) natural killer (NK) cell therapy is a genetically modified lymphocyte product. The starting cells may be autologous or allogeneic, and the introduced receptor combines an antigen-binding domain with intracellular signaling domains. Product designs may also include cytokine-support or logic-gating components. FDA states that many of the chemistry, manufacturing, and controls, pharmacology and toxicology, and clinical recommendations in its CAR-T guidance are expected to apply to related genetically modified lymphocyte products, including CAR-NK cells.^[S1]

Product-design approaches

No CAR-NK product appears on FDA's list of approved cellular and gene therapy products, current as of August 18, 2026.^[S3] The categories below are therefore product-design approaches, not approved-product examples and not a ranking.

Cord-blood-derived CAR-NK with IL-15 expression

One design starts with cord-blood-derived NK cells and introduces a CAR together with an IL-15 expression cassette. For a program using this design, characterize CAR and IL-15 expression, growth and viability, and the relationship between administered cells and measured persistence. Treat cytokine expression as a product-specific safety variable as well as a design feature.

iPSC-derived CAR-NK

An iPSC-derived approach introduces genetic changes at the pluripotent-cell stage and differentiates the banked cells into NK cells. Candidate constructs may combine a CAR with other receptor or signaling modifications. Commissioning questions include clonal and bank characterization, differentiation consistency, residual undifferentiated cells, post-thaw identity and potency, and comparability after manufacturing changes.

NK-92-cell-line-derived CAR-NK

A cell-line-derived approach uses NK-92 cells as the manufacturing substrate. For such a product, define the controls used to limit proliferation and evaluate how those controls affect viability, potency, and cellular kinetics. The specific cell bank, genetic construct, manufacturing process, and release strategy should drive the test plan.

Development questions

Persistence and expansion

Measure how long administered cells remain detectable, whether they expand, and where they distribute. Link those measurements to the administered dose and to product attributes such as viability and cytokine-support design. These data describe cellular kinetics in the selected test system; they do not predict persistence or treatment effect in patients.

Inhibitory signaling and the tumor microenvironment

CAR signaling operates alongside the NK cell's endogenous activating and inhibitory receptor network. Design the assay panel to test whether HLA class I-dependent inhibitory signaling, soluble factors such as TGF-beta, or hypoxic culture conditions change the product's measured cytotoxicity. Report these as effects in the defined assay system, not as proof of behavior in a human tumor.

Gene transfer and post-thaw function

Gene-transfer efficiency, CAR-positive cell fraction, viability, recovery, and potency should be measured at release and after the actual freeze-thaw and handling procedure intended for the clinical site. A post-thaw result is only interpretable when the assay time point, recovery period, cell concentration, and acceptance criteria are defined in advance.

A product-specific nonclinical program

1. Model selection, biodistribution, and cellular kinetics

Select an animal model only after defining which questions it can answer about the human product. FDA advises considering immunodeficient animals when they permit longer assessment of a human cell therapy product.^[S4] For a CAR-NK program, a sponsor may pair a validated nucleic-acid assay for CAR sequences with imaging or tissue analysis to measure biodistribution and persistence. Because model suitability and cytokine support are product specific, discuss the proposed model and its limitations with CBER before committing to the pivotal program.^[S2]

2. Phenotype and function under defined stress conditions

Characterize both CAR-mediated activity and the endogenous receptor phenotype. Depending on the question, scRNA-seq, CITE-seq, or mass cytometry can measure receptors such as KIR, NKG2A, and TIGIT together with cytotoxic-effector markers. Use prespecified comparisons to determine how the measured phenotype changes under the selected culture or tumor-model conditions; do not interpret those conditions as a complete simulation of a patient's tumor microenvironment.

3. Post-thaw viability and potency

Test the product after the same thawing, hold time, and administration preparation planned for clinical use. A panel may include viability and recovery, real-time cell analysis for cytotoxicity, CD107a degranulation, and response to repeated antigen challenge. The panel should show which product attributes change after thawing and whether the lot meets predefined release or stability criteria.

4. Allogeneic and unintended-activity risks

For an allogeneic product, the program should address residual T cells, graft-versus-host disease potential, on-target activity in non-tumor tissue, unintended activity, and host alloimmune responses. Possible components include sensitive detection of residual CD3-positive cells, mixed-lymphocyte assays, and tissue or organoid panels selected for the target. These assays inform risk characterization and lot controls; they do not establish a clinical safety margin on their own. FDA's framework calls for a nonclinical program tailored to the cell product rather than a fixed conventional repeat-dose toxicology package.^[S4]

Questions for a testing laboratory

Ask a laboratory to identify which assays it performs in-house, how it validates cellular-kinetics and potency methods, whether it can test the final post-thaw product, and how it links samples across biodistribution, phenotype, and functional endpoints. Require the proposal to state the limitations of each model and how the study design follows the product's intended route and clinical use. For questions not resolved by the CAR-T guidance, FDA recommends early discussion with CBER.^[S1][S2] A future licensed CAR-NK product would proceed through CBER's Biologics License Application pathway.^[S5]